Tripep's evaluation of GPG® continues

Tripep's evaluation of GPG® continues In-depth analysis of the results of the CTN 002 status report continues. A number of possible explanations for the negative result are being investigated in order to find an effective administration form for GPG®. Following consultation with the Clinical Advisory Board, it has been decided that the remaining patients in the CTN 002 study, which is a per oral treatment study, will complete their treatment. No additional patients will be included in the study, which will then be closed. A final report will be presented once the study is completed. For further information, please contact: Hans Möller, President and CEO, tel. +46-8-449 84 80, mobile +46-708-15 16 89, e-mail: hans.moller@tripep.se. ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2001/09/25/20010925BIT00760/bit0001.doc http://www.waymaker.net/bitonline/2001/09/25/20010925BIT00760/bit0001.pdf